Abstract

En masse phenotyping technology, using massively mosaic donor-derived cells and organoids, can offer enriched insights for cellotype–phenotype association in a cell-type-specific regulatory context. This emerging approach will help to discover biomarkers, inform genetic–epigenetic interactions and identify personalized therapeutic targets, offering hope for precision medicine against highly heterogeneous metabolic diseases.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call